Caris Doctor Testimonials

By comparing the unique biomarkers of a patient's cancer with clinical studies from thousands of the world's leading cancer researchers, Caris Life Sciences Molecular Intelligence^™ Service helps physicians create personalized therapy regimens that are suited to their patient's specific cancer. The results from several cases have oncologists talking about the benefits they've experienced thanks to these innovative services.

Learn more about the innovation behind evidence-based molecular profiling at CarisMolecularIntelligence.com or learn how to order our services for your patients.

Molecular Intelligence^™ Service, from Caris Life Sciences^®, provides evidence-based tumor information that associates biomarker status to agents with potential clinical benefit or potential lack of clinical benefit. Agents associated with clinical benefit are presented based on NCCN Compendium^™ inclusion, relevance of tumor type, level of published evidence and strength of biomarker expression. Report information must be considered in conjunction with all other relevant information in respect of a given patient before determining the appropriate course of treatment. The selection of agents for re-treatment from prior chemotherapy regimens lies with the treating physician and must be done with careful consideration. Caris Molecular Intelligence Service was developed and its performance characteristics were determined by Caris Life Sciences, a medical laboratory CLIA-certified in compliance with the U.S. Clinical Laboratory Amendment Act of 1988 and all relevant U.S. state regulations. Caris Molecular Intelligence Service has not been approved by the United States Food and Drug Administration.